Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adapting antibodies for clinical use.

R E Hawkins1, M B Llewelyn, S J Russell

  • 1Medical Research Council Centre, Cambridge.

BMJ (Clinical Research Ed.)
|November 28, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PIWIs, piRNAs and Retrotransposons: Complex battles during reprogramming in gametes and early embryos.

Reproduction in domestic animals = Zuchthygiene·2017
Same author

High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma.

Blood cancer journal·2017
Same author

Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains.

Leukemia·2017
Same author

Pomalidomide-dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial.

Leukemia·2017
Same author

Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma.

Blood cancer journal·2017
Same author

Natural history of t(11;14) multiple myeloma.

Leukemia·2017
Same journal

Doctors are fighting to protect children from mouldy homes after death of Awaab Ishak.

BMJ (Clinical research ed.)·2026
Same journal

Delayed discharges: Annual cost rises to almost £2.7bn in past year.

BMJ (Clinical research ed.)·2026
Same journal

The UK's social media ban is a gamble in the face of uncertainty.

BMJ (Clinical research ed.)·2026
Same journal

Wegovy weight loss pill now available to UK patients-how will it affect doctors?

BMJ (Clinical research ed.)·2026
Same journal

Endometriosis: "Game changing" new tests may speed up diagnosis in primary care.

BMJ (Clinical research ed.)·2026
Same journal

Consultants vote for industrial action in England.

BMJ (Clinical research ed.)·2026
See all related articles

Advancements in antibody engineering are enabling routine clinical use of monoclonal antibodies. These engineered antibodies can target treatments and reduce immune responses, leading to wider therapeutic applications.

Area of Science:

  • Biotechnology
  • Immunology
  • Pharmacology

Background:

  • Monoclonal antibodies (mAbs) have shown therapeutic potential but faced challenges in routine clinical application.
  • Limitations included immunogenicity and difficulties in targeted delivery of treatments.

Purpose of the Study:

  • To review recent advancements in antibody engineering techniques.
  • To highlight how these techniques overcome previous limitations for clinical use.
  • To discuss the implications for the future of monoclonal antibody therapeutics.

Main Methods:

  • Chemical and genetic manipulation of antibodies.
  • Engineering of antibody binding sites for reduced immunogenicity (e.g., humanization).
  • In vitro gene amplification and bacteriophage display for library generation and antibody production.

Related Experiment Videos

Main Results:

  • Antibodies can be conjugated with toxins, enzymes, radionuclides, or drugs for targeted therapy.
  • Humanization of mouse-derived antibody binding sites reduces immunogenicity.
  • Large-scale production of specific human monoclonal antibodies is now feasible.

Conclusions:

  • Antibody engineering is overcoming historical barriers to routine clinical use.
  • These advancements facilitate targeted therapies and improved patient outcomes.
  • A significant increase in the clinical application of monoclonal antibodies is anticipated.